Sana has emerged with funding from investors including F-Prime Capital, Arch and Flagship Pioneering to develop genetically modified hypoimmogenic stem cells.

Harvard University’s Office of Technology Development yesterday announced it had executed a licence agreement with its US-based spinout Sana Biotechnology for stem cell medicines resistant to immune system rejection. Sana Biotechnology launched in January 2019 with an undisclosed sum of funding from F-Prime Capital, a branch of financial services group Fidelity, as well as from…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.